London Cancer Urology Pathway Board

Transcription

1 Urology Pathway Board Date: Thursday, 5 September 2014, 16:00 18:00 Venue: Meeting Room 1,, 3 rd Floor, 170 Tottenham Court Road, W1T 7HA Chair: John Hines, Pathway Director 1. Welcome, Introductions and Apologies (JH) JH welcomed members of the board, introductions were made and apologies heard. agreed as an accurate records of the last meeting. Minutes were 2. Review of minutes of the last meeting and action log (JH) Local cancer campaign on the agenda. Research sub group Dr Karen Tipples (clinical oncologist Barts) will replace Katherine Piggott joining the other 3 members who are Prof Mark Emberton, Prof John Kelly and Prof Tom Powles. NC asked how the PB board could or should be part of the discussion as well as how the pathway board can add value. It was agreed to ask TP who is the link to the pathway. JH to send an invite to the research meeting being held at UCLH in Jan. A uro-pathology meeting will be held in November and is to be chaired by Tom Powles. The MRI meeting has just taken place today (25 th ) previous to this board and the minutes will be circulated once confirmed by those who attended the meeting. Bladder pathway meeting that has taken at UCLH JH will send the minutes to KM for circulation. ACTION: JH to send a save the date for the Research meeting in January at UCLH ACTION: CL to out minutes from MRI meeting ACTION: JH to send minutes from the UCLH bladder pathway meeting to KM to circulate 3. update / NHSE is reorganising in order to adapt its available resources to the evolving requirements of the partner trusts and to support the AHSN focus on defragmenting patient pathways, delivery of innovation and accelerating implementation of improvement. The CEOs in the partnership recognise and value the clinical leadership supported by London Cancer, which has delivered many achievements in the past two years. UCLPartners is committed to continuing support to the integrated cancer programme. Our future objectives continue to be supporting innovation in early diagnosis, improving patient experience and increasing access to and participation in research. The governance of will change from 1 October As the system takes on greater ownership for delivery, the skills-based Board will be replaced by the Chief Medical Officer reporting directly to the UCLPartners Executive. This was agreed by the UCLPartners Executive on 8 September and will be communicated to external audiences in early October. 1

2 The Pathway Boards and Expert Reference Groups will continue to operate, but will meet with less frequency and will receive administrative support from until end March There will no longer be pathway management support for the Pathway Board, but will provide admin support to arrange meetings, track attendance and take minutes. In order to meet with Peer Review requirements, Boards will meet up to four times a year with light touch secretariat / admin support confirmed until March There will no longer be admin support for the Pathway Board subgroups. continues to prioritise Early Diagnosis and will focus on key areas of innovation which may impact across several different pathways, e.g. straight to test for earlier diagnosis of colorectal symptoms. is also looking to test a multi-disciplinary diagnostic centre for vague abdominal symptoms to streamline a diagnostic route for these patients. Work will continue to be prioritised and supported for implementation of the NCSI recovery package and Stratified Follow-up. This is being supported through a Macmillan funded workstream. All pathway boards can access project support for quality improvement initiatives that are aligned with the priorities of the wider system. This will be supported through UCLPartners improvement model to accelerate delivery across the partnership. Reimbursement to the Trusts from /UCLPartners for the clinical leadership will be reduced. We are continuing to work with NHS England s Transforming Cancer Services team for London to ensure alignment with the Five year Cancer commissioning Strategy for London. The Macmillan workstreams are still being supported. There will also be an addition to the team as a GP is being appointed to work on the early detection and awareness programme. It was noted that the pathway board has been successful in some of its annual aims but the area of research is still behind in seeing the benefits in terms of increase in clinical trials. NC noted that the work programme had been completed and agreed and this should be revisited in light of ML s update. JH agreed and that this should be on the next agenda. ACTION: The Urology Pathway Board work programme to be revisited on the next agenda 4. Peer review update Peer review was moved forward in the agenda. JS highlighted a letter written by Sian Hallaway, Chair of the National User Steering Group to David Cameron complaining about the proposed changes to peer review. It is considered that peer review, which sits with NHSIQ (part of the NHS) is under threat. Currently there has been no response that we know of to the letter (the letter will be sent out with the minutes) JS feels strongly the peer review process needs to remain external and funded. MY highlighted that an audit regarding self-assessments showed that Trusts rated themselves on average 20% higher than achieved through external assessments. ML noted other levers could be used other than peer review and used the example that another pathway board have considering setting themselves up to monitor Trusts against compliance against specifications & agreed pathways. ML also noted that there was possible future in greater powers with Trust contracts and with greater penalties (no penalties associated with peer review). There was also discussion at the national level about the CQC amending its approach to incorporate the peer review challenges to a Trust. 2

3 JS requested that the PB write a letter of support to the peer review process. NC suggested that the full facts around the future proposals be known first. JH suggested writing to the CQC to ask how it intended to cover peer review. SG noted he would highlight the issue at the NCIN meeting that is taking place in 2 weeks time. It was agreed that as a group the pathway board could express the fact it was worried about future changes to the peer review process. ACTION: JH to write a letter to the NHSIQ / NHS England regarding the peer review process on behalf of the pathway board members 5. 2 week wait form All the comments that had been sent to SG and CM had been taken on board and appropriate changes made. Further guidance was discussed and changes agreed It was agreed that the 2 week wait form could be signed off by the pathway board. 6. Stratified follow update A stratified follow up care meeting had taken place on 28 th Aug It was agreed a sub group would focus on this workstream which is being supported by Sharon Cavanaugh at. It was noted that John Sandell, Jane Smith and Christine Moss will be on the sub group. 7. Be Clear on Cancer campaign Public Health England are launching an initiative around prostate cancer awareness in London (3 boroughs in the North; Haringey, Hackney and Newham in the region and 3 in the South have been selected). The initiative will run as a one month pilot to raise awareness particularly amongst black men. It is aimed to encourage the men to see their GP and to discuss with the GP their prostate cancer risk. The idea is to see if awareness is increased. Materials for GP will also be available for GPs. The pilot will be fully evaluated. The pilot is set to start on 20 Oct. It has purposely set itself up alongside the blood in pee campaign. Marketing has been organised that is precise to the particular communities. The campaign will be working with the black media The campaign has suggested that 45 year olds onwards go and talk to their GPs Posters have been sent to CCGs, TSCT and local health watch There is a plan to use social media as part of this, e.g. twitter, Facebook, celebrities and their social media platforms There will be liaison with the black majority churches and mosques in the areas involved A number of social events in these areas happening during this time are also being targeted NC asked what will be the measurements of success. The answer is that the Be Clear on Cancer metrics will be used including for example the survey in the community pre and post and qualitative work and focus groups. The Acute Trusts have been made aware of the campaign. 3

4 8. AOB (All) JG (cancer programme director at UCLH) explained the structure that has been set up to take forward the changes of the Case for Change. There is a specific Operational Steering Group for each of the 5 pathways. Each of the OSGs will report to the Cancer Unification Board (CUB) which will comprise on at a minimum medical directors, pathway board leads, academic leads and patients. CUB will report to the London Joint Programme Board and Trust boards. 9. Next Meeting The next Pathway Board meeting will be held on 27 November, at 16:30 in Meeting Room 1 at offices, 3 rd Floor, 170 Tottenham Court Road, W1T 7HA. 4

5 ACTION LOG Action Owner Date agreed Status PB members to send any ideas on Early Diagnosis & how to raise awareness to JH Save the date for the Research meeting in January at UCLH to be circulated ALL 12 Jun 2014 ongoing CL 24 Jul 2014 asap JH / Pathway Directors to establish a programme of education JH 24 Jul 2014 TBD CL to out minutes from MRI meeting CL 25 Sep Nov 2014 JH to send minutes from the UCLH bladder pathway meeting to KM to circulate The Urology Pathway Board work programme to be revisited on the next agenda JH to write a letter to the NHSIQ / NHS England regarding the peer review process on behalf of the pathway board members JH, KM 25 Sep Nov 2014 All 25 Sep Nov 2014 JH 25 Sep Nov

6 Attendees John Hines Urologist Barts Health Christine Moss General Practitioner GP - West Essex CCG Cid O Sullivan Clinical Nurse Specialist Royal Free London - Hampstead Claire Levermore Pathway Manager Clare Stevenson Clinical Psychologist Homerton University Hospital Frank Chinegwundoh Urologist Barts Health Jane Smith Patient Representative Patient Representative Jeevan Kumaradevan Consultant Radiologist The Whittington Hospital John Sandell Patient Representative Patient Representative Michael Aitchison Consultant Urologist, Director renal cancer Royal Free London - Hampstead Michael Yare Clinical Adviser, Transforming Cancer Services Cancer Commissioning Team Team - NEL Commissioning Support Unit Neil Cameron Patient Representative Patient Representative Sacha Ali Clinical Nurse Specialist Homerton University Hospital Sandeep Gujral Urologist Barking, Havering and Redbridge University Hospitals Veronica Brinton Patient Representative Patient Representative Also Present Jaspal Virdi on behalf of Jolanta McKenzie Urologist PAH Luis Beltran Barts Health Hilary Baker UCLH Mairéad Lyons Director of Integrated Cancer Jonathan Gardner Programme Director Cancer Change Apologies Jolanta McKenzie Medical Director Princess Alexandra Hospital Sharon Cavanagh Survivorship Lead Thomas Powles Medical Oncologist Barts Health No Apologies Guy Webster Urologist Royal Free London - Barnet and Chase Farm Harshawardhan Godbole Urologist North Middlesex University Hospital Katharine Pigott Clinical Oncologist Royal Free London - Hampstead/ University College London Hospitals Lois Roberts Manager University College London Hospitals 6